Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma Academic Article uri icon


MeSH Major

  • Nanoparticles
  • Proteins
  • Surface Plasmon Resonance


  • Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults. DLBCL exhibits highly aggressive and systemic progression into multiple tissues in patients, particularly in lymph nodes. Whole-body (18)F-fluodeoxyglucose positron emission tomography ([(18)F]FDG-PET) imaging has an essential role in diagnosing DLBCL in the clinic; however, [(18)F]FDG-PET often faces difficulty in differentiating malignant tissues from certain nonmalignant tissues with high glucose uptake. We have developed a PET imaging strategy for DLBCL that targets poly[ADP ribose] polymerase 1 (PARP1), the expression of which has been found to be much higher in DLBCL than in healthy tissues. In a syngeneic DLBCL mouse model, this PARP1-targeted PET imaging approach allowed us to discriminate between malignant and inflamed lymph nodes, whereas [(18)F]FDG-PET failed to do so. Our PARP1-targeted PET imaging approach may be an attractive addition to the current PET imaging strategy to differentiate inflammation from malignancy in DLBCL.

publication date

  • September 5, 2017



  • Academic Article



  • eng

PubMed Central ID

  • PMC5594659

Digital Object Identifier (DOI)

  • 10.1073/pnas.1705013114

PubMed ID

  • 28827325

Additional Document Info

start page

  • E7441

end page

  • E7449


  • 114


  • 36